نتائج البحث - Mark D. Pegram

تنقيح النتائج
  1. 1
    Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

    Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer حسب Mark D. Pegram, Christian Jackisch, Stephen Johnston

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Triple negative breast cancer: unmet medical needs

    Triple negative breast cancer: unmet medical needs حسب Sumanta K. Pal, Barrett H. Childs, Mark D. Pegram

    منشور في 2010
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

    Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs حسب Richard J. Pietras, Mark D. Pegram, Richard S. Finn, Daniel A Maneval, Dennis J. Slamon

    منشور في 1998
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

    The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells حسب Mark D. Pegram, Richard Finn, Karo K. Arzoo, Malgorzata Beryt, Richard J. Pietras, Dennis J. Slamon

    منشور في 1997
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Hydrogel Pore‐Size Modulation for Enhanced Single‐Cell Western Blotting

    Hydrogel Pore‐Size Modulation for Enhanced Single‐Cell Western Blotting حسب Todd A. Duncombe, Chi‐Chih Kang, Santanu Maity, Toby M. Ward, Mark D. Pegram, Niren Murthy, Amy E. Herr

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Extracellular Vesicle–Mediated <i>In Vitro</i> Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity

    Extracellular Vesicle–Mediated <i>In Vitro</i> Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity حسب Alexis V. Forterre, Jing‐Hung Wang, Alain Delcayre, Kyuri Kim, Carol Green, Mark D. Pegram, Stefanie S. Jeffrey, A. Matin

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Role of Fcγ receptors in HER2-targeted breast cancer therapy

    Role of Fcγ receptors in HER2-targeted breast cancer therapy حسب Antonino Musolino, William J. Gradishar, Hope S. Rugo, Jeffrey L. Nordstrom, Edwin P. Rock, Fernanda I. Arnaldez, Mark D. Pegram

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

    Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831 حسب Nadine Norton, Rebecca M. Olson, Mark D. Pegram, Kathleen Tenner, Karla V. Ballman, Raphael Clynes, Keith L. Knutson, Edith A. Perez

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer حسب Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Immune cell repertoires in breast cancer patients after adjuvant chemotherapy

    Immune cell repertoires in breast cancer patients after adjuvant chemotherapy حسب Claire E. Gustafson, Rohit R. Jadhav, Wenqiang Cao, Qian Qi, Mark D. Pegram, Lü Tian, Cornelia M. Weyand, Jörg J. Goronzy

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study حسب Nancy U. Lin, Mark D. Pegram, Solmaz Sahebjam, Nuhad K. Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney P. Kirschbrown, Priya Kumthekar

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review

    Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review حسب Hope S. Rugo, Giuseppe Curigliano, Fátima Cardoso, WJ Gradishar, Mark D. Pegram, C.H.H. Barrios, J. Cortés Castán, Eduardo J. Pennella, Rafael Muniz

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer

    Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–pos... حسب Xavier Pivot, Mark D. Pegram, Javier Cortés, Diana Lüftner, Gary H. Lyman, Giuseppe Curigliano, Igor Bondarenko, Ye Chan Yoon, Younsoo Kim, Chul Kim

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

    Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens حسب Kimberly Blackwell, Mark D. Pegram, Elizabeth Tan-Chiu, Lee S. Schwartzberg, Michael Arbushites, Julie Maltzman, John Forster, S. D. Rubin, Steven H. Stein, Harold J. Burstein

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation

    Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation حسب Jing‐Hung Wang, Alexis V. Forterre, Jinjing Zhao, Daniel O. Frimannsson, Alain Delcayre, Travis J. Antes, Bradley Efron, Stefanie S. Jeffrey, Mark D. Pegram, A. Matin

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

    Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer حسب José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna Samant, Steve Olsen, Sanne Lysbet de Haas, Mark D. Pegram

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall... حسب Véronique Dièras, David Miles, Sunil Verma, Mark D. Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim T. Blackwell, Silke Hoersch, Jin Xu, Marjorie Green, Luca Gianni

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

    Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 حسب Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, H. Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, Mark D. Pegram, José Baselga, Larry Norton

    منشور في 2001
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer

    Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer حسب Marzia Locatelli, Philippe Aftimos, Elizabeth Claire Dees, Patricia LoRusso, Mark D. Pegram, Ahmad Awada, Bo Huang, Rossano Cesari, Yuqiu Jiang, M. Naveed Shaik, Kenneth A. Kern, Giuseppe Curigliano

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer حسب Mark D. Pegram, Erika Hamilton, Antoinette R. Tan, Anna Maria Storniolo, Kemal Balic, Anton I. Rosenbaum, Meina Liang, Peng He, Shannon Marshall, Anita Scheuber, Mayukh Das, Manish R. Patel

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: